SLC35A3 Remodels Site-Specific N-Glycosylation and Defines a Druggable Glycosylation Target in Hepatocellular Carcinoma
Authors:
- Qin OuyangQOQin Ouyang
- Ke GaoKGKe Gao
- Xinwen ZhouXZXinwen Zhou
- Jieyi ShiJSJieyi Shi
- Long LiaoLLLong Liao
- Cun WangCWCun Wang
- Shu ZhangSZShu Zhang
Open Access
- 5 October 2026
- journal article
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (11)
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (82150111)
This publication has 27 references indexed in Scilit:
- The Biological Basis and Analyses of N-Glycan MicroheterogeneityMolecular & Cellular Proteomics, 2025
- TMEM241 is a UDP-N-acetylglucosamine transporter required for M6P modification of NPC2 and cholesterol transportJournal of Lipid Research, 2023
- The role of N-glycosylation in cancerActa Pharmaceutica Sinica B, 2023
- Protein glycosylation alterations in hepatocellular carcinoma: function and clinical implicationsOncogene, 2023
- The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United StatesClinical Gastroenterology and Hepatology, 2022
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- Integrated Proteogenomic Characterization of HBV-Related Hepatocellular CarcinomaCell, 2019
- Nucleotide Sugar Transporter SLC35 Family Structure and FunctionComputational and Structural Biotechnology Journal, 2019
- Targeting mutant p53 for efficient cancer therapyNature Reviews Cancer, 2017
- Factors controlling the glycosylation potential of the Golgi apparatusTrends in Cell Biology, 1998